Search results
Brokerage Radar: NBFC, Bank stocks in focus; Indegene gets sell call, Polycab rated overweight
CNBC Awaaz· 2 days agoDiscover the latest brokerage calls and analyst insights on active stocks and sectors today,...
PFC, REC get 'buy' rating from Bernstein; up to 23% upside seen in power financier stocks
CNBC Awaaz· 3 days agoREC has delivered multibagger returns of 224 percent in one year, more than quadrupling investors'...
Taking Stock: Market bounces back; Nifty at 24,150, Sensex up 443 points
CNBC Awaaz· 4 days agoTop Nifty gainers included Tech Mahindra, Wipro, Bajaj Finance, UltraTech Cement and Grasim...
RIL's market capitalisation to swell by up to $100 billion, predicts Morgan Stanley
CNBC Awaaz· 4 days agoOver the past three decades, RIL has delivered 2-3x returns for shareholders, with each decade...
Bite-sized content! Social media marketing tips you didn’t know you needed
Financial Express· 4 days agoMastering the dos and don’ts of social media marketing is key to staying afloat and thriving. What...
Taking Stock: Market hits new milestone; bank, metal, power outshine
CNBC Awaaz· 2 days agoAmong sectors, except media, all other sectoral indices ended in the green with power, capital...
Subscribe- Long Term Emcure Pharmaceuticals Ltd; Anand Rathi
CNBC Awaaz· 3 days agoAnand Rathi, has come out with its report on Emcure Pharmaceuticals Ltd. The research firm has recommended to “ Subscribe- Long Term” the ipo in its research report as on July 02 2024.
HFT Scan: Ceat and India Cements in focus
CNBC Awaaz· 5 days agoCeat and India Cements closed higher on June 28.
Allied Blenders and Distillers: Should you buy, sell or hold after listing?
CNBC Awaaz· 3 days agoWhile promising macro situation are likely to help the company experience growth, the issue seems to...
Emcure Pharma IPO: Issue subscribed 29% on Day 1 so far; NIIs lead from the front
CNBC Awaaz· 3 days agoA day before the drugmaker's public offer went live, Emcure Pharmaceuticals raised Rs 582.6 crore...